Elevated Lp(a) and course of COVID-19: Is there a relationship?
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
08
2021
accepted:
28
03
2022
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Lipoprotein (a)-Lp(a) has proinflammatory, prothrombotic and proatherogenic properties and may theoretically influence the course of COVID-19. The aim of the study was to explore whether patients hospitalized due to COVID-19 with Lp(a) ≥30mg/dl may develop a worse course of the disease, increased incidence of thromboembolic complications, intubation and ICU hospitalization or death. A retrospective analysis was performed of 124 patients hospitalized due to COVID-19 in the Department of Internal Diseases and Clinical Pharmacology between 29 November 2020 and 15 April 2021. The only exclusion criterion was age≥80 years. Patients were divided into two groups: 1. COVID-19 patients with Lp(a) <30mg/dl regarded as not elevated n = 80; 2. COVID-19 patients with Lp(a) ≥30 regarded as elevated n = 44. A total of 124 COVID-19 patients were included in the study (66 men and 58 women) with a mean age of 62.8±11 years. COVID-19 patients with elevated Lp(a) level had significantly longer hospitalization time (11 vs. 9.5 days; p = 0.0362), more extensive radiological changes in CT scan (35 vs. 30%; p = 0.0301) and higher oxygen demand on admission (8 vs. 5L/min; p = 0.0428). Elevated Lp(a) was also associated with significantly higher OR for High Flow Nasal Oxygen Therapy (HFNOT) OR = 3.5 95%CI(1.2;8.9), p = 0.0140, Intubation and ICU OR = 4.1 95%CI(1.1;15.2) p = 0.0423, Death OR = 2.8 95%CI(0.9;8.5), p = 0.0409. Elevated Lp(a) might be one of the factors which contribute to a more severe course of COVID-19; however, further studies including larger groups of patients are needed.
Sections du résumé
BACKGROUND
Lipoprotein (a)-Lp(a) has proinflammatory, prothrombotic and proatherogenic properties and may theoretically influence the course of COVID-19.
OBJECTIVES
The aim of the study was to explore whether patients hospitalized due to COVID-19 with Lp(a) ≥30mg/dl may develop a worse course of the disease, increased incidence of thromboembolic complications, intubation and ICU hospitalization or death.
PATIENTS AND METHODS
A retrospective analysis was performed of 124 patients hospitalized due to COVID-19 in the Department of Internal Diseases and Clinical Pharmacology between 29 November 2020 and 15 April 2021. The only exclusion criterion was age≥80 years. Patients were divided into two groups: 1. COVID-19 patients with Lp(a) <30mg/dl regarded as not elevated n = 80; 2. COVID-19 patients with Lp(a) ≥30 regarded as elevated n = 44.
RESULTS
A total of 124 COVID-19 patients were included in the study (66 men and 58 women) with a mean age of 62.8±11 years. COVID-19 patients with elevated Lp(a) level had significantly longer hospitalization time (11 vs. 9.5 days; p = 0.0362), more extensive radiological changes in CT scan (35 vs. 30%; p = 0.0301) and higher oxygen demand on admission (8 vs. 5L/min; p = 0.0428). Elevated Lp(a) was also associated with significantly higher OR for High Flow Nasal Oxygen Therapy (HFNOT) OR = 3.5 95%CI(1.2;8.9), p = 0.0140, Intubation and ICU OR = 4.1 95%CI(1.1;15.2) p = 0.0423, Death OR = 2.8 95%CI(0.9;8.5), p = 0.0409.
CONCLUSIONS
Elevated Lp(a) might be one of the factors which contribute to a more severe course of COVID-19; however, further studies including larger groups of patients are needed.
Identifiants
pubmed: 35675355
doi: 10.1371/journal.pone.0266814
pii: PONE-D-21-27400
pmc: PMC9176856
doi:
Substances chimiques
Lipoprotein(a)
0
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266814Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circulation. 2016 Aug 23;134(8):611-24
pubmed: 27496857
Curr Atheroscler Rep. 2020 Jul 25;22(9):48
pubmed: 32710255
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711
pubmed: 28183512
Eur J Clin Invest. 2021 Sep;51(9):e13629
pubmed: 34184268
Front Med (Lausanne). 2021 Jan 20;7:629413
pubmed: 33553222
Circulation. 2019 Mar 19;139(12):1493-1496
pubmed: 30883219
Circulation. 2020 Jun 2;141(22):1826-1828
pubmed: 32479194
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474
pubmed: 33115266
Blood. 2000 Nov 15;96(10):3364-8
pubmed: 11071628
J Intern Med. 2020 Jan;287(1):2-18
pubmed: 31858669
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Theranostics. 2021 Jan 1;11(1):316-329
pubmed: 33391477
J Lipid Res. 2018 Apr;59(4):577-585
pubmed: 29378781
Atherosclerosis. 2016 Mar;246:214-20
pubmed: 26803430
J Am Heart Assoc. 2019 Jun 4;8(11):e012638
pubmed: 31140334
Cardiovasc Drugs Ther. 2016 Feb;30(1):87-100
pubmed: 26896185
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
J Intern Med. 2022 Jan;291(1):101-107
pubmed: 34096654
Heart. 2021 Mar;107(5):373-380
pubmed: 33334865
J Am Coll Cardiol. 2018 Jan 16;71(2):177-192
pubmed: 29325642
J Lipid Res. 2016 May;57(5):745-57
pubmed: 26647358